Managing PSOriasis in the REAL world: One-year prospective, observational study of the journey of patients with plaque psoriasis prescribed calcipotriol/betamethasone aerosol foam or other topical therapy (PSOREAL)

Study identification

• EU PAS number:
  EUPAS45322
• Study ID:
  45655
• Official title and acronym:
  Managing PSOriasis in the REAL world: One-year prospective, observational study of the journey of patients with plaque psoriasis prescribed calcipotriol/betamethasone aerosol foam or other topical therapy (PSOREAL)
• DARWIN EU® study:
  No
• Study countries:
  Canada

  Sweden

  United Kingdom
• Study description:
  12-months non-interventional, multinational, multi-site study in a prospective cohort study of adult patients suffering from psoriasis vulgaris and treated with topical therapy.
• Study status:
  Finalised

Research institutions and networks

Institutions

Multiple centres: 101 centres are involved in the study

Study timelines

Date when funding contract was signed

Actual:21/03/2016

Study start date

Actual:12/01/2017

Date of final study report

Actual:10/11/2021

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

LEO Pharma

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable